3-(苄氧基)-4-甲基苯胺 | 219492-12-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 3-(苄氧基)-4-甲基苯胺
• 英文名称: 3-(benzyloxy)-4-methylaniline
• 英文别名: 3-benzyloxy-4-methylaniline；3-benzyloxy-4-methyl-aniline；3-Benzyloxy-4-methyl-anilin；4-methyl-3-phenylmethoxyaniline
• CAS: 219492-12-3
• 化学式: C₁₄H₁₅NO
• 分子量: 213.279
• InChiKey: TZWRMTAIHRIAFC-UHFFFAOYSA-N

物化性质

• 沸点：
  369.3±27.0 °C(Predicted)
• 密度：
  1.106±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2922199090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H312,H315,H319,H332,H335

SDS

Name:	3-(Benzyloxy)-4-methylphenylamine 97% Material Safety Data Sheet
Synonym:	None Known
CAS:	219492-12-3

Section 1 - Chemical Product MSDS Name:3-(Benzyloxy)-4-methylphenylamine 97% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
219492-12-3	3-(Benzyloxy)-4-methylphenylamine	97%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 219492-12-3: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 130 deg C @ 0.05mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C14H15NO
Molecular Weight: 213.28

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, acid chlorides.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 219492-12-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-(Benzyloxy)-4-methylphenylamine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing Group: III
IMO
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing Group: III
RID/ADR
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 23 Do not inhale gas/fumes/vapour/spray.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 219492-12-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 219492-12-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 219492-12-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(苄氧基)-4-甲基苯胺 在 XPhos 、 palladium 10% on activated carbon 、 氢气 、 palladium diacetate 、 caesium carbonate 、 溶剂黄146 作用下， 以 甲醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 192.0h， 生成 carbalexin B
  参考文献：
  名称：

  通过硼酸催化的吡喃环环合成7和8加氧的吡喃并[3,2-a]咔唑和吡喃并[2,3-a]咔唑生物碱

  摘要：

  柠檬酸的硼酸催化环化为氧化环化单萜类吡喃咔唑生物碱开辟了一条捷径。因此，从相应的咔唑前体中仅可通过三个步骤获得murrayamine-D，总产率为55％。

  DOI：

  10.1002/chem.201403143
• 作为产物：
  描述：

  2-苄氧基-4-硝基甲苯 在 铁粉 、 溶剂黄146 作用下， 反应 4.0h， 以100%的产率得到3-(苄氧基)-4-甲基苯胺
  参考文献：
  名称：

  吡喃并[3,2-a]咔唑的有效构建：在仿生全合成环化单萜类吡喃并[3,2-a]咔唑生物碱中的应用

  摘要：

  我们已经开发了一种通过钯催化的咔唑骨架构建2-羟基-3-甲基咔唑（1）的高效途径。使用1作为中继化合物，已经测试了通过与萜类结构单元反应而使吡喃环环化的不同方法。路易斯酸促进的1与醛（21）的反应开辟了一条生成吉利比滨（3）的有效途径，相应的与柠檬醛（25）的反应得到了马哈宁（5）。化合物3和5的氧化提供了murrayacine（4）和murrayacinine（6）。根据生物遗传学的建议，马哈宁（5）已被用于有效的仿生合成环化单萜吡喃并[3,2– a ]咔唑生物碱环马哈宁（7），马尼苯丁（8）和双环马哈宁（9）。的互变5，7，8和9中描述和机械影响进行了讨论。通过X射线晶体结构确定明确地验证了结构分配。此外，将环马哈宁滨（7）转化为murrayazolinine（10）和exozoline（11）。

  DOI：

  10.1002/chem.201301792

文献信息

• [EN] COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR<br/>[FR] COMPOSÉS, COMPOSITIONS ET MÉTHODES PERMETTANT DE MODULER LE CFTR
  申请人：PROTEOSTASIS THERAPEUTICS INC

  公开号：WO2017062581A1

  公开（公告）日：2017-04-13

  The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.

  本公开涉及揭示的化合物，可以调节，例如，解决CFTR活性细胞处理中的潜在缺陷。
• First Total Synthesis of 7-Isovaleryloxy-8-methoxygirinimbine
  作者：Christian Brütting、Arndt Schmidt、Olga Kataeva、Hans-Joachim Knölker

  DOI：10.1055/s-0037-1609717

  日期：2018.7

  Abstract We describe the first total synthesis of the pyrano[3,2-a]carbazole alkaloid 7-isovaleryloxy-8-methoxygirinimbine, using a palladium(II)-catalyzed double C–H-bond activation for construction of the carbazole framework and a phenylboronic acid catalyzed annulation of the pyran ring as key steps. We describe the first total synthesis of the pyrano[3,2-a]carbazole alkaloid 7-isovaleryloxy-8-methoxygirinimbine

  摘要 我们描述了吡喃并[3,2- a ]咔唑生物碱7-异戊酰氧基-8-甲氧基吉里宁的第一个全合成，使用钯（II）催化的双CH键结合构造咔唑骨架和苯硼酸酸催化吡喃环的环化为关键步骤。 我们描述了吡喃并[3,2- a ]咔唑生物碱7-异戊酰氧基-8-甲氧基吉里宁的第一个全合成，使用钯（II）催化的双CH键结合构造咔唑骨架和苯硼酸酸催化吡喃环的环化为关键步骤。
• Total Synthesis of the Biscarbazole Alkaloids Murrafoline A-D by a Domino Sonogashira Coupling/Claisen Rearrangement/Electrocyclization Reaction
  作者：V. Pavan Kumar、Konstanze K. Gruner、Olga Kataeva、Hans-Joachim Knölker

  DOI：10.1002/anie.201305993

  日期：2013.10.11

  at a time? Aryl–pyran‐linked biscarbazole alkaloids of the murrafoline group (see crystal structure of murrafoline A; dark gray: C, red: O, blue: N) were accessed readily by a novel domino reaction sequence involving Sonogashira coupling, a Claisen rearrangement, and electrocyclization. The one‐pot procedure enables the straightforward synthesis of these structurally challenging alkaloids in only a

  为什么每次只迈出一步？通过涉及Sonogashira偶联，克莱森重排和电环化。一锅法操作仅需几个步骤即可直接合成这些结构上具有挑战性的生物碱。
• Palladium(II)-Catalyzed Synthesis of the Formylcarbazole Alkaloids Murrayaline A-C, 7-Methoxymukonal, and 7-Methoxy-<i>O</i>-methylmukonal
  作者：Ronny Hesse、Micha P. Krahl、Anne Jäger、Olga Kataeva、Arndt W. Schmidt、Hans-Joachim Knölker

  DOI：10.1002/ejoc.201402201

  日期：2014.7

  We describe the synthesis of the naturally occurring 2,7-dioxygenated formylcarbazole alkaloids 7-methoxymukonal, 7-methoxy-O-methylmukonal, and the murrayalines A–C. The carbazole framework was constructed by a Buchwald–Hartwig amination and a subsequent palladium(II)-catalyzed oxidative cyclization.

  我们描述了天然存在的 2,7-双氧合甲酰咔唑生物碱 7-甲氧基 mukonal、7-甲氧基-O-methylmukonal 和 murrayalines A-C 的合成。咔唑骨架是通过 Buchwald-Hartwig 胺化和随后的钯（II）催化氧化环化构建的。
• [EN] ANTITHROMBOTIC AGENTS<br/>[FR] AGENTS ANTITHROMBOTIQUES
  申请人：ELI LILLY AND COMPANY

  公开号：WO1999000121A1

  公开（公告）日：1999-01-07

  (EN) This application relates to a compound of formula (I) (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.(FR) Cette invention traite d'un composé de la formule (I), telle que définie dans le descriptif, (ou bien d'un promédicament de ce composé ou bien d'un sel pharmaceutiquement acceptable de ce composé ou d'un promédicament de ce composé), de compositions pharmaceutiques contenant ce composé, de l'utilisation de ce composé en tant qu'inhibiteur du facteur Xa, d'un procédé permettant de préparer ce composé et d'intermédiaires utilisés pour produire ledit composé.

  该申请涉及公式（I）的化合物（或其前药或化合物或前药的药学上可接受的盐），其药物组成，以及其作为因子Xa的抑制剂的用途，以及其制备过程和中间体。